To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission.

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

Selmi, Carlo;
2021

Abstract

To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission.
arthritis
biological therapy
psoriatic
therapeutics
Adult
Antirheumatic Agents
Arthritis, Psoriatic
Cohort Studies
Female
Humans
Interleukin-12
Interleukin-23
Male
Middle Aged
Prospective Studies
Treatment Outcome
Tumor Necrosis Factor Inhibitors
Ustekinumab
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11699/68655
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact